Pistoia Alliance Launches Pharma Innovation Council and Appoints New Chief Portfolio Officer to Drive Global Industry Collaboration
Newly appointed CPO and 13 Council members will work to boost adoption of emerging technologies, tackle R&D challenges, and empower patients, with new projects that will overcome common industry barriers.
Boston, March 7, 2023: The Pistoia Alliance, a global, not-for-profit alliance that advocates for greater collaboration in life sciences R&D has launched the Pistoia Alliance Pharma Innovation Council. Led by Alliance President Dr Becky Upton, the 13 next-generation leaders from large global pharmaceutical companies reflect the diversity of membership viewpoints. The Council will explore common challenges at a grassroots level and seed ideas for new pre-competitive projects aligned with the Alliance’s strategic themes: Emerging sciences and Technology, Improving the Efficiency and Effectiveness of R&D, and Empowering the Patient.
The Council is supported by the Alliance’s new Chief Portfolio Officer, Dr Hall Gregg, who brings 30 years’ experience as a technology leader in the life sciences industry. Dr Gregg has held senior positions at Merck, Amgen and Pfizer as well as American Red Cross and Quest Diagnostics; her expertise spans digital strategy, data analytics, cyber and data security, organizational transformation, and talent development. Dr Gregg has led global technology organizations to create successful digital products and services that deliver value and impact, and is passionate about supporting diversity in STEM.
“I joined the Pistoia Alliance because I see global collaboration as the key to unlocking the life science industry’s expertise,” commented Dr Hall Gregg, Chief Portfolio Officer, Pistoia Alliance. “I am looking forward to working with colleagues and peers to advance the application of technology in life sciences and healthcare. The outputs from the Alliance’s portfolio of projects will accelerate research, improve responses to global health challenges, and most importantly, improve patients’ lives.”
The Pharma Innovation Council aims to produce one new project idea per theme and will bring together interested parties from member companies who could benefit from and want to invest in driving forwards these new initiatives. Common industry challenges that emerged at the first meeting of the Council include the automation of data analysis, enabling the Lab of the Future, and the development of industry standards to enable collaboration. New projects will sit alongside the Alliance’s current portfolio of projects, now overseen by Dr Hall, which includes the IDMP Ontology Project, DataFAIRy Bioassay Annotation Project and Diversity & Inclusion in STEM Leadership program.
“By bringing in the next generation of diverse thinkers to create new Pistoia Alliance projects, we can keep doing what we do best – advancing collaboration in the life sciences,” commented Dr Becky Upton, President, Pistoia Alliance. “Our aim is to develop projects with tangible outcomes that shape the future of our industry. We were founded on the principle that breakthroughs in science are not made alone. With our new Council, and by bringing in Dr Hall to lead our portfolio, our commitment to working together to achieve success is stronger than ever.”
The inaugural meeting of the Council took place in January 2023. The Council will meet again on April 25th to discuss their new project proposals. The 13 members are collaborating under the following three working groups aligned with the Pistoia Alliance’s key strategic themes:
Improving the Efficiency and Effectiveness of R&D
Emerging Sciences and Technology
Empowering the Patient
To find out more about the Pistoia Alliance’s portfolio of member-driven projects visit www.PistoiaAlliance.org
About The Pistoia Alliance:
The Pistoia Alliance is a global, not-for-profit members’ organization made up of life science companies, technology and service providers, publishers, and academic groups working to lower barriers to innovation in life science and healthcare R&D. It was conceived in 2007 and incorporated in 2009 by representatives of AstraZeneca, GSK, Novartis, and Pfizer who met at a conference in Pistoia, Italy. Its projects transform R&D through pre-competitive collaboration. It overcomes common R&D obstacles by identifying the root causes, developing standards and best practices, sharing pre-competitive data and knowledge, and implementing technology pilots. There are currently over 200 member companies; members collaborate on projects that generate significant value for the worldwide life sciences R&D community, using the Pistoia Alliance’s proven framework for open innovation.
+44 207 436 0420
The Pistoia Alliance
+44 7887 811332